FDA Inspection 1094205 — Jazz Pharmaceuticals, Inc

Jazz Pharmaceuticals, Inc — FEI 3005615655

The FDA completed an inspection of Jazz Pharmaceuticals, Inc on June 10, 2019 in Palo Alto, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 3 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
June 10, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Palo Alto, CA (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
21355FDCA 505-1(f)(3)(B)Failure to comply with REMS Elements to Assure Safe Use (ETASU) B
673221 CFR 314.80(c)(1)(i)Late submission of 15-day report
684221 CFR 314.80(j)Failure to maintain records